Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant
October 15 2019 - 9:00AM
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company, today announced the addition of Scott
Applebaum to its team as lead strategic regulatory consultant. Mr.
Applebaum possesses over two decades of industry experience working
with public and private companies handling regulatory interactions
with the FDA and international regulatory agencies, global drug
launches, company-wide corporate and legal affairs and merger and
acquisition activities.
“We are thrilled to have Scott join the Seelos team as lead
strategic regulatory consultant. His extensive experience
navigating the global regulatory process and overseeing successful
global drug launches will make him a major asset for us,” said Raj
Mehra, Chairman and CEO of Seelos.
Mr. Applebaum most recently served as President of
privately-owned Context Therapeutics and General Counsel and
Secretary at Vitae Pharmaceuticals. At Vitae, he worked closely
with the CEO and Board of Directors on the successful sale of the
clinical stage biopharmaceutical company to Allergan
Pharmaceuticals for $639 million, a 159% premium to its
then-publicly traded market value. Prior to those roles, he served
as Corporate Secretary for Medgenics, Inc., a clinical stage,
publicly traded biotech company and spent 10 years at Shire
Pharmaceuticals.
During his tenure at Shire, Mr. Applebaum helped to build the
company’s global CNS-focused footprint where he led the strategy
and execution of its legal, regulatory, and commercial functions.
He held several senior roles at Shire including General Manager of
International ADHD, Global Head of Regulatory Affairs, and Global
Neuroscience Business Unit Head. Before Shire, for seven years he
had roles of increasing responsibility in the legal department of
Bristol-Myers Squibb Company.
“I am excited to work with Raj and the top-notch team he has
assembled at Seelos,” said Mr. Applebaum. “I look forward to
helping them advance their encouraging pipeline of
programs focused on unmet needs in CNS disorders and rare
diseases."
Mr. Applebaum earned a Juris Doctor from Stanford Law School,
where he was on the law review, and a B.S. in Economics from
Wharton School, University of Pennsylvania, from which he graduated
summa cum laude. He was admitted to the Pennsylvania and New Jersey
bars, and is a certified public accountant (CPA).
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and advancement of novel
therapeutics to address unmet medical needs for the benefit of
patients with central nervous system (CNS) disorders and other rare
disorders. The Company's robust portfolio includes several
late-stage clinical assets targeting psychiatric and movement
disorders, including orphan diseases. Seelos is based in New York,
New York. For more information, please visit our website:
http://seelostherapeutics.com, the content of which is not
incorporated herein by reference.
Contact Information: Anthony Marciano Head of Corporate
Communications Seelos Therapeutics, Inc. (Nasdaq: SEEL) 300 Park
Ave., 12th Fl New York, NY 10022 (646) 293-2136
anthony.marciano@seelostx.com www.seelostherapeutics.com https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
Seelos Therapeutics (NASDAQ:SEEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seelos Therapeutics (NASDAQ:SEEL)
Historical Stock Chart
From Apr 2023 to Apr 2024